The Lancet
Publisher: Elsevier · ISSN 0140-6736 · 93 articles
- A blended digital parenting intervention for the prevention of sexual violence, exploitative sex, and maltreatment of children at scale in Tanzania: a cluster-randomised, controlled trial
- A digital intervention to strengthening parenting in Tanzania
- Reframing disease elimination: an update from the Lancet Commission on chronic obstructive pulmonary disease
- Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial
- Lynch syndrome
- Lula's new term—safeguarding science, health, and the Amazon
- Emerging Shamonda virus: a new threat to pregnancy?
- Cangrelor for myocardial infarction-related cardiogenic shock
- Health and poverty: lessons from China
- Optimising late-line treatment administration in metastatic colorectal cancer: an even brighter SUNLIGHT
- Is chemotherapy still needed in all patients with mismatch repair-deficient advanced or recurrent endometrial cancer?
- The overlooked role of CMV in pneumonia in infants with HIV
- Empirical tuberculosis treatment in infants living with HIV: missed opportunities and ways to improve outcomes
- Beyond poverty eradication: what China's health and poverty alleviation experience means for global health
- Governing artificial intelligence for reliable research
- Offline: Anthony Fauci comes to London
- WHO's next Director-General
- Access to medicines: innovations not reaching those in need
- Do Not Go Gentle: The Case Against Assisted Death, Kathleen Stock. The Bridge Street Press/Little, Brown Book Group (2026), 296, £22·00, ISBN: 9780349136646
- Ron McCoy
- The Perth Declaration to eliminate rheumatic fever and rheumatic heart disease
- WHO's operational role in emergencies: a view from Gaza
- Evidence and gaps for preventing postpartum haemorrhage
- Evidence and gaps for preventing postpartum haemorrhage – Authors’ reply
- Department of Error
- 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
- First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
- Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial
- Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial
- A Lancet Commission on the Health and Poverty Alleviation Initiative in China